



IRIDEX

MicroPulse P3[®] Device

Versatile and Non-Incisional Glaucoma Treatment with
MicroPulse[®] Transscleral Laser Therapy

- A success rate of 60% to 80%¹⁻¹⁷
- Achieves IOP reduction of 30% to 45%^{1, 3, 6, 9-15, 17, 18}
- Durability of up to 72 months with 3 retreatments¹⁹
- Over 120,000 patients treated in 60 countries
- Leaves future treatment options open



iridex.com/MicroPulseP3

Re-Thinking Glaucoma Care

MICROPULSE® TRANSSCLERAL LASER THERAPY (TLT)

A cost-effective combination of safety, efficacy, durability and repeatability in a non-incisional approach to glaucoma care. MicroPulse Transscleral Laser Therapy via the MicroPulse P3® Device offers you and your patients a therapy which can be introduced prior to, in conjunction with and following all other available glaucoma treatment options, and the ability to treat at several different time points throughout the course of the disease.

- A success rate of 60% to 80%¹⁻¹⁷
- Leaves future treatment options open
- Achieves IOP reduction of 30% to 45%^{1, 3, 6, 9-15, 17, 18}
- Durability of up to 72 months with 3 retreatments¹⁹
- Used in 38 of the 39 best hospitals in the United States**
- Reduction in drug burden in eye drops and oral medications^{1-4, 6-13, 18}
- Revised probe now available with improved ease of use, visualization, fit, and coupling
- Limited amount of immediate follow-up
- Patient downtime is significantly low
- Low investment for high utility
- Economic savings to patients
- Covered under CPT 66710 in the U.S.A.***





Patients to Consider*

- Maximum tolerated medical therapy and compliance issues
- Pre trabeculectomy, stent or filter
- Failed trabeculectomy, stent or filter
- Eyes with compromised ocular surface

Clinical Evidence

More than 120,000 procedures performed in 60 countries since 2015



SAFE

Over 70 studies show consistently low adverse events



EFFECTIVE

Over 70 studies show sustained IOP reduction, some with 30-45% in 60-85% of patients



DURABLE

Over 500 eyes in studies demonstrating durability greater than 12 months





VERSATILE

Over 500 eyes in studies demonstrating durability greater than 12 months



Surgical Guide

1. A viscous, liquid interface (e.g. methyl cellulose) must be utilized to ensure proper light coupling to the conjunctiva. Place a drop on the undersurface of the probe footplate. Reapply as necessary. Not using a liquid interface could result in loss of up to 40% of energy.
2. Orient the probe with the wide, curved side (bunny ears) aligned at the surgical limbus to ensure consistent treatment application. Be sure to view from directly above to avoid placement error because of parallax.
3. Maintain the footplate of the probe flat against the conjunctiva throughout the treatment with constant, gentle pressure. Do not rock the probe while sweeping.
4. Use 2500 mW, 50 seconds per hemisphere, and a duty cycle of 31.3%.
5. Sweep the probe along the limbus in an arc of 150 degrees for 10 seconds (avoid the 3 and 9 o'clock positions). Maintain a constant velocity during each pass.
6. Reverse the direction and repeat for a total of 5 passes.





As I saw the results and how comfortable my patients were, I started to expand its use, and now I use it for various types of glaucoma cases."



Sandra Fernando Sieminski, MD
Ross Eye Institute
Buffalo, NY USA



The revised MicroPulse P3 Device is intuitive and easy to use. The design delivers energy in a much more consistent fashion and allows for very stable contact on the sclera."



Brian A. Francis, MD
Doheny Eye Institute, UCLA

Cyclo G6® Laser: Specifications

Wavelength	810 nm infrared
Weight	4.8 kg (10.5 lb)
Dimensions	27 cm x 29.5 cm x 19.7 cm (10.6" W x 11.6" D x 7.8" H)
Connector Type	SmartProbe RFID with Laser Parameter Memory
Electrical	100-240 VAC, 50/60 Hz, <0.8 A
Cooling	Air cooled
Exposure Duration	CW-Pulse: 10 ms – 9000 ms in 606 increments and continuous pulse up to 60 seconds
Exposure Interval	CW-Pulse: 10 – 3000 ms in 598 increments and One Pulse
MicroPulse® Duration	MicroPulse: 0.05-1.0 ms in 19 increments
MicroPulse Interval	MicroPulse: 1.0-10.0 ms in 90 increments
MicroPulse Duty Cycle	Continuously adjustable from 0.5%-50%, and preset selections of 5%, 10%, and 15% duty cycles
Aiming Beam	Diode laser, 635 nm nominal
Treatment Power	50-3000 mW, depending on delivery device



Ordering


Product	Product Number	Units per Box
MicroPulse P3® Device	15522	6
Cyclo G6® Laser	CYCLO-G6-SYSTEM	

The MicroPulse P3 Device is a single-use device. Specifications are subject to change without notice. Products are covered by one or more of the following U.S. patents: 5,511,085; 5,982,789; 6,327,291; 6,540,391; 6,733,490; 7,766,904; 7,771,417; 7,909,816; 5,997,498; 6,073,759; 6,092,898; 6,217,594; 6,494,314; 6,585,679; 6,726,666; 6,800,076; 6,866,142; 7,537,593; 8,177,777; 8,945,103; 783,783; 69530497.6; KR 348012; 0904615; 69706541.3; CA 2331837; AU 759193; JP 4149670; EP 1009684; CA 2286002; JP 449444; JP 4570696; JP 4819754; JP 5123973; JP 5133069. U.S. and international Patents Pending may apply.

¹ Zaarour K, et al. J Glaucoma 2019. ² Subramaniam K, et al. Cornea 2019. ³ Nguyen AT, et al. Eur J Ophthalmol 2019. ⁴ Barac R, et al. Romanian J Ophthalmol 2018. ⁵ Sanchez FG, et al. Arch Soc Esp Ophthalmol 2018. ⁶ Lee JH, et al. J Glaucoma 2017. ⁷ Sarrafpour S, et al. Ophthalmology Glaucoma 2019. ⁸ Awoyesuku EA, et al. JAMMR 2019. ⁹ Abdelrahman AM, et al. J Glaucoma 2018. ¹⁰ Aquino MC, et al. Clin Exp Ophthalmol 2015. ¹¹ Jammal AA, et al. Arq Bras Oftalmol 2019. ¹² Tan A, et al. Clin Experiment Ophthalmol 2010. ¹³ Williams AL, et al. J Glaucoma 2018. ¹⁴ Varikuti VNV, et al. J Glaucoma 2019. ¹⁵ Souissi S, et al. Eur J Ophthalmol 2019. ¹⁶ Magacho L, et al. Lasers Med Sci 2019. ¹⁷ Magacho L, et al. J Glaucoma 2019. ¹⁸ Yelenskiy A, et al. J Glaucoma 2018. ¹⁹ Aquino M, et al. European Glaucoma Society 2016.

*Indications for the MicroPulse P3 Device include, but are not limited to transscleral cyclophotocoagulation for the treatment of primary open-angle glaucoma, closed-angle glaucoma, and refractory glaucoma. **As ranked by U.S. News and World Report. *** National reimbursement for CPT code 66710 in the United States is as follows: \$453 for physician payment in physician office, \$400 for physician payment in ASC, \$836 for facility payment in ASC, \$400 for physician payment in hospital outpatient department, and \$1,934 for facility payment in hospital outpatient department.

EC REP Emergo Europe
Prinsessegracht 20, 2514 AP The Hague, The Netherlands



IRIDEX • 1212 Terra Bella Avenue • Mountain View, CA 94043 • U.S.A.
800.388.4747 (U.S.A. only) • 1.650.940.4700 • glaucoma@iridex.com • iridex.com/MicroPulseP3

© 2020 IRIDEX. All rights reserved. IRIDEX, the IRIDEX logo, Cyclo G6, MicroPulse, and MicroPulse P3 are trademarks or registered trademarks of IRIDEX. LT0723.C 06.2020